In the last video I shared a success. Today I want to share the other side. A man in his early thirties. AIDS. Kaposi’s sarcoma. And the conversation that has stayed with Dr. Alberto ever since.
▶ Watch the full video on YouTube
Infectious Diseases in Focus →Not every story from medical residency ends the way you hope. In the last video, I described the child with meningococcemia who recovered because a diagnosis was made from the skin alone, before the lab results came back. That was the other kind of story. Today I want to tell you about the kind that stays with you differently — the kind where medicine reaches its limit, and you have to say so.
He was a man in his early thirties. He had AIDS, and he was being treated for Kaposi’s sarcoma — a malignant tumor that had spread extensively across his skin, including his face and legs. The lesions were large and visible. His face had become partially deformed by the disease. He had been hospitalized for several weeks.
At the time — around 1990 or 1991 — the treatment available for Kaposi’s sarcoma in AIDS patients was interferon alfa and vinblastine. Interferon alfa modulates immune activity; vinblastine is a chemotherapy agent. Both could be injected directly into isolated lesions, or administered intravenously when the disease was as extensive as his. It was the standard approach of the era.
Kaposi’s sarcoma is caused by Human Herpesvirus 8 — HHV-8 — a member of the herpes family. In most people with intact immune systems, HHV-8 infection is kept in check and causes no disease. In patients with severe immunosuppression — such as those with advanced AIDS, where CD4 T-cell counts fall dramatically — the virus can activate, invade vascular endothelial cells, and trigger their uncontrolled proliferation. The result is a tumor of vascular origin that can appear anywhere the body’s blood vessel network reaches: the skin (most visibly), the lungs, the intestines, the muscles, lymph nodes.
Before effective antiretroviral therapy existed, Kaposi’s sarcoma was a defining feature of the AIDS epidemic — particularly in the early 1980s and through the 1990s. It was one of the conditions that first alerted clinicians in the United States that something new and devastating was occurring in the immune systems of young patients.
One day, after weeks of hospitalization and treatment, the patient came to Dr. Alberto with a question.
He left. Dr. Alberto was left with a feeling he describes as one of the greatest sorrows of his residency — not directed at the patient, not at himself, but at the situation itself. At the limits of what medicine could offer. At the gap between what a patient needs and what a doctor can give.
In 1990, the available HIV treatment was AZT (zidovudine) alone, or in some cases AZT combined with DDI (didanosine). Two drugs. Limited efficacy. Unable to adequately suppress viral replication or reconstruct immune function in most patients.
The transformation came with triple combination antiretroviral therapy — three or more drugs from different classes, which became the standard of care in the mid-1990s. The effect on Kaposi’s sarcoma was dramatic and, to many clinicians, almost astonishing: by restoring immune function, ART allowed the body to suppress HHV-8 naturally. Kaposi’s sarcoma lesions regressed — often without any specific anti-Kaposi’s treatment at all.
The same principle applies to every AIDS-defining opportunistic condition. Cerebral toxoplasmosis. Pneumocystis jirovecii pneumonia (formerly PCP). Cryptococcal meningitis. Cytomegalovirus disease. These conditions emerged because the immune system could no longer suppress the pathogens that a healthy immune system keeps dormant. Restore the immune system — which modern ART can do — and the opportunistic infections regress or fail to recur.
Dr. Alberto describes this case as one that “left a profound and lasting mark.” Not because the outcome was preventable — with the tools available in 1990, it was not. But because it illustrated something that every clinician encounters and that no training fully prepares you for: the moment when medicine reaches its limit, and you must stand in that gap with your patient, honestly.
Infectious disease medicine, like all of medicine, has two sides. There are the successes — the meningococcemia patient who recovered because a doctor looked at the skin and acted before the results came back. And there are the cases where the disease is faster, the tools are insufficient, and the best you can offer is honesty and presence. Both experiences are real. Both shape what kind of physician you become.